96%

Within 6 months of launch we were able to detect through feedback from stakeholders.

96% Treatment Independence: In the Phase 3 PaTHway trial, 96% of participants using the therapy and support tools achieved independence.

89%

89% Long-Term Retention: The app and companion program contributed to an exceptionally high 89% patient retention rate over a 3.5-year period.

Survey

Secondary research informed survey questions regarding habits, injection pen perceptions, treatment methods, and peak health times.

Social groups

I used social groups as a safe, trusted platform to gather honest patient experiences.

Secondary research

I conducted secondary research to deepen understanding of the condition, specifically targeting symptoms, user behavioral patterns, and medication details.

From my secondary research I was able to generate a domain knowledge and define key pain points.

38 daily-medicated respondents reported irregular symptoms, with 87% favoring injection pens.

47% of respondents keep a track record of their daily medications and supplements, while 34% do not, and 18% do so only sometimes.

“Wouldn’t bother me if it improves my quality of life.”

Common tracking methods include pill containers, diaries, the Medisafe app, alarms, Google Calendar, and Alexa.

While 66% have used an injection pen previously, a higher 87% expressed a willingness to take medication via an injection pen.

To learn how to use an injection pen, respondents preferred information from booklets (19), infovideos (18), HCPs (17), and support forums (13).

Who are my users?

Impaired daily functioning, Supplement longevity concerns, Desire for peer support, Anxiety over medical extremes and Anxiety over medical extremes.

Pains?

Loss of independence, Debilitating physical symptoms, Frustrating lack of energy, Dismissive HCP interactions, Profound social isolation, Longing for former life.